Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686198 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
A Phase 2 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07686198: Clinical Trial Phase 2 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
NCT07686198 is a Phase 2 study that has not yet begun recruiting, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07686198, a Phase 2 study, has not yet begun recruiting, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective is to compare Re-Q Pro-Longevity serum versus vehicle serum combined with Intense Pulsed Laser for the treatment of moderate to severe photodamage and crepiness on the dorsal forearms.
Primary Outcome
Physician assessed aesthetic improvement. All assessments will be made on 5-point scale (Circle One) 1. Very much improved 2. Much improved 3. Improved 4. No change 5. Worse
Interventions
- DRUG Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy
- DRUG Left Arm treated with vehicle serum and Intense Pulsed Light Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-10 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
What is known before NCT07686198 opens enrollment
NCT07686198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy is the first listed.
NCT07686198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07686198 about?
NCT07686198 is a clinical study titled "Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms". The primary objective is to compare Re-Q Pro-Longevity serum versus vehicle serum combined with Intense Pulsed Laser for the treatment of moderate to severe photodamage and crepiness on the dorsal forearms.
What is the current status of trial NCT07686198?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-07-10. Estimated completion is 2027-01-30.
What interventions are being tested in trial NCT07686198?
The interventions under investigation include: Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy (DRUG), Left Arm treated with vehicle serum and Intense Pulsed Light Therapy (DRUG).
Who is sponsoring clinical trial NCT07686198?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07686198's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI